NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Regend Therapeutics

Regend Therapeutics

Private
SuzhouHealthcare & Life Scienceshttps://regend.cn/

Last Round

Series C

Feb 11, 2026

Total Funding Raised

$67.68M

Company Overview

Regend Therapeutics is a biotechnology company that specializes in organ regeneration through progenitor cell-based regenerative medicine.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

regenerative medicinesmall molecule drugsbiotechdrug discoverycontract development and manufacturing organizationCDMOendogenous stem cellstissue regenerationpredictive analyticsclinical trial optimizationdegenerative diseasebiopharmaAI drug discoveryin vivo regenerationcell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Regend Therapeutics Comparables

Compare Regend Therapeutics with similar companies based on industry and business-model similarity.

Regend Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Audion Therapeutics
78%
Regeneron Pharmaceuticals
68%
Zehui Biotechnology
65%

Regend Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 11, 2026
Series BMar 3, 2022
AngelAug 6, 2015

Regend Therapeutics Investors

Notable investors and investment history

Regend Therapeutics investors
InvestorRounds
China Merchants SecuritiesSeries B
Soochow SecuritiesSeries B
Wanrong HongtuSeries B
West Fountain Capital Management LimitedSeries B
Hefei Hi-Tech VCSeries C
Shenzhen Capital GroupSeries B

Regend Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Regend Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Regend Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range5
Year Founded2015
Last FundingFeb 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.